

REGISTRATION COMING SOON

12th International Pediatric Renal Tumor Biology Meeting

JUNE 5-7, 2024

Memorial Sloan Kettering Cancer Center
Zuckerman Research Center
417 East 68th Street, New York, NY

CALL FOR ABSTRACTS

Abstract submission deadline: March 15, 2024



Memorial Sloan Kettering
Cancer Center

This three-day live symposium at Memorial Sloan Kettering focuses on the biology and clinical translation of emerging research in pediatric renal tumors, particularly Wilms tumor as well as RCC and other rare childhood kidney tumors.

The symposium will consist of **didactic lectures, poster sessions**, as well as **focused breakout discussions**; the latter being focused on pre-clinical pediatric renal tumor models and prioritizing targets and therapies for advanced Wilms tumors. This large, but focused, gathering of scientists, clinicians, and other key stakeholders will provide significant opportunities for both learning and networking.

WEDNESDAY, JUNE 5, will initially begin with an educational overview of pediatric renal tumors prior to the scientific meeting commencement in order to provide a foundational basis for attendees with varied backgrounds. The afternoon launches the formal symposium with a focus on the renal biological processes, both physiologic and pathologic, that lead to the development of childhood kidney tumors. There will be a particular focus on renal regeneration and repair as well as advances in our understanding of clonal nephrogenesis.

THURSDAY, JUNE 6, will focus on advances in our understanding of the genomics, epigenomics, and proteomics of childhood kidney tumors. This will include discussion on topics such as cancer predisposition, clonal evolution, intratumoral heterogeneity, preclinical tumor models, and emerging technologies such as circulating tumor DNA.

FRIDAY, JUNE 7, will transition towards more clinically actionable investigations, consisting of talks related to immunotherapy, targeted therapies, and current and emerging clinical trials including novel study designs. There will be a particular focus on rare non-Wilms renal tumors, such as renal cell carcinoma, rhabdoid tumor, and childhood kidney sarcomas.

CALL FOR ABSTRACTS

We invite the submission of abstracts for this program.

Abstracts will be selected for the poster session on the basis of their scientific merit and content quality. Authors of accepted abstracts will receive presentation and registration instructions upon acceptance.

The abstract submission deadline is March 15, 2024.

Abstract acceptance notifications will be emailed to all authors in mid-April.

TARGET AUDIENCE & LOCATION

This symposium is intended for pediatric renal tumor clinicians, researchers, and students.

This program is set to be an exclusively in-person event at Memorial Sloan Kettering's Zuckerman Research Center.

Zuckerman Research Center
417 East 68th Street
New York NY, 10065

Ample time will be provided during this program and throughout the symposium social events for networking and professional collaboration.

Registration will be available online soon:
msk.org/cme

SYMPOSIUM DIRECTOR



Michael V. Ortiz, MD

Assistant Attending
Department of Pediatrics
Memorial Sloan Kettering Cancer Center
New York, NY

SYMPOSIUM CO-DIRECTOR



Alex Kentsis, MD, PhD

Director, Tow Center for Developmental Oncology
Associate Member
Department of Pediatrics
Memorial Sloan Kettering Cancer Center
New York, NY

SCIENTIFIC PLANNING COMMITTEE



James (Jim) Geller, MD

Director, Liver, Kidney and Retinoblastoma Programs;
Director, Advanced Cancer Therapy Network,
Cancer and Blood Disease Institute
Director, Pilot Translational Core Grant Program,
Center for Clinical and Translational Science and Training
Cincinnati Children's Hospital
Cincinnati, OH



Manfred Gessler, MD

Chair of Developmental Biochemistry
University of Wuerzburg
Würzburg, Germany



Andrew Hong, MD

Assistant Professor, Department of Pediatrics
Emory University School of Medicine
Children's Healthcare of Atlanta
Atlanta, GA



Elizabeth Mullen, MD, FAAP

Program Leader, Renal/Liver Tumors
Institute Physician
Assistant Professor of Pediatrics,
Harvard Medical School
Dana Farber Cancer Institute
Boston, MA



Marry van den Heuvel-Eibrink, MD, PhD

Chair, SIOP Renal Tumor Study Group
Chair, Comprehensive Renal Cancer Center and
PI Princess Máxima Center
Utrecht, Netherlands



Arnauld Verschuur, MD, PhD

Senior Consultant, Pediatric Oncology
Hôpital d'Enfants de La Timone
Marseille, France

KEYNOTE PRESENTERS



Marjolijn Jongmans, MD, PhD

Clinical Geneticist and Co-Principal Investigator
The Princess Máxima Center
Utrecht, Netherlands



Brian D. Crompton, MD

Research Co-Director, Solid Tumor Center
Dana-Farber Cancer Institute
Boston, MA

Memorial Sloan Kettering Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.



John Anderson, PhD

Consultant Paediatric Oncologist
University College London
London, England



Benjamin Dekel, MD, PhD

Chief, Pediatric Nephrology
Director, Pediatric Stem Cell Research Institute
Sheba Medical Center
Ramat Gan, Israel



Sam Behjati, MA, BMBCh, PhD, MRCPCH

Group Leader & Wellcome Senior Research Fellow
Wellcome Trust Sanger Institute
Hixton, England



Elizabeth (Lisa) Petri Henske, MD

Director of the Center for LAM Research and Clinical Care
Brigham and Women's Hospital
Boston, MA

GUEST SPEAKER



Conrad Fernandez, MD

Professor Emeritus
Dalhousie University
Halifax, Nova Scotia, Canada

Registration will be available online soon:

msk.org/cme

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

[msk.org/cme](https://www.msk.org/cme)



Memorial Sloan Kettering
Cancer Center